Business Update Positive

2026-11-06 20:48

Current scenario - Delivered Q2 FY27 revenue from operations of INR 7,827 crores, up 11% YoY. - EBITDA margins stood at 25.1% for the quarter, supported by strong performance in India and Other Developed Markets. - U.S. business impacted by increased competition and loss of exclusivity on key products like Tolvaptan, recording USD 317 million. Management Guidance & Outlook - Reaffirmed FY27 revenue growth goals and EBITDA margin guidance of around 24%-25%. - U.S. revenues for FY27 expected in the range of USD 1.1 billion to USD 1.2 billion, maintaining USD 1 billion+ for FY28. - India formulations business projected to grow at 1.2x to 1.3x the Indian Pharmaceutical Market (IPM) growth rate. Growth Drivers & Pipeline - Strong momentum in India driven by chronic therapies, led by anti-diabetes and cardiac segments. - Expanding specialty capabilities in Europe via acquisitions like VISUfarma and the addition of Yuvezzi. - Robust U.S. pipeline including complex injectables, respiratory products, 505(b)(2) filings like Apixaban Oral Suspension, and biosimilars.

Business Update Neutral

2026-11-04 21:19

- Audio recording of Earnings Call for Q2 FY27 results (quarter ended September 30, 2026) is available on the company's website. - The conference call was held on November 04, 2026, at 18:00 IST.

Business Update Positive

2026-11-04 01:51

- Q2 FY27 Sales stood at ₹77,855 mn, up 14% YoY; Net Income rose 22% YoY to ₹11,553 mn. - EBITDA reached ₹19,574 mn with an EBITDA margin of 25.1%. - India sales grew 15% YoY to ₹23,836 mn; North America rose 10% YoY. - Plans to launch 20+ products in India and ~15 in the US during FY27.

Financials Neutral

2026-11-04 01:45

Q2 FY27 Consolidated Revenue ₹7,827.3 Cr vs ₹7,047.5 Cr (▲11.1% YoY) EBITDA ₹2,044.5 Cr vs ₹2,341.3 Cr (▼12.7% YoY) PAT ₹1,155.3 Cr vs ₹1,484.8 Cr (▼22.2% YoY) EBITDA Margin 26.1% vs 33.2% (▼710bps)

Governance Neutral

2026-11-04 01:13

Lupin Limited has appointed Mr. Akhil Gupta as an Additional Director (Non-Executive, Independent) effective November 03, 2026. He has been appointed for a term of five consecutive years from November 03, 2026, to November 02, 2031, subject to shareholder approval.

Financials Neutral

2026-11-04 00:46

Q2 FY27 Consolidated Revenue ₹7,827.3Cr vs ₹7,047.5Cr (▲11% YoY) EBITDA ₹2,044.4Cr vs ₹2,341.3Cr (▼13% YoY) PAT ₹1,155.3Cr vs ₹1,484.8Cr (▼22% YoY) EBITDA Margin 26.1% vs 33.2% (▼710bps)

Business Update Positive

2026-11-03 19:39

- Lupin Limited announced the launch of Raltegravir Tablets, USP, 600 mg in the United States. - The product is bioequivalent to Isentress HD Tablets, 600 mg of Merck Sharp & Dohme, LLC. - Lupin is the exclusive first-to-file and is eligible for 180-day generic drug exclusivity. - The target product had an estimated annual sale of USD 26 million in the U.S. (IQVIA MAT September 2026).

Business Update Positive

2026-11-02 18:12

- Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application for Amifampridine Tablets, 10 mg. - The product is bioequivalent to Firdapse Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc. - Lupin is the First-To-File and is eligible for 180-day shared generic exclusivity.

Business Update Neutral

2026-10-24 14:26

- Lupin Limited informed that the U.S. FDA concluded an inspection at its manufacturing facility in Goa, India, from October 19 to October 23, 2026. - The inspection closed with the issuance of a Form-483 containing one observation. - The company stated it will address the observation and respond to the U.S. FDA within the stipulated timeframe.

Routine Neutral

2026-10-23 16:39

- Lupin Limited has allotted 3,033 fully paid-up equity shares of ₹2/- each on October 23, 2026, pursuant to the exercise of vested options under the company's ESOP. - The total issued and paid-up share capital of the company has increased to ₹91,45,86,010, consisting of 45,72,93,005 equity shares.

Governance Neutral

2026-10-23 10:01

- Lupin Limited has appointed Brian Savage as President and Chief Legal Officer, effective October 23, 2026. - He will lead the global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions, based in New Jersey. - Brian previously served in senior leadership roles, including Interim Global Chief Legal Officer, at Teva Pharmaceuticals.

Governance Neutral

2026-10-22 22:31

- Lupin Limited has appointed Mr. Brian Savage as Senior Management Personnel, designated as President and Chief Legal Officer, effective October 22, 2026. - He will oversee the company's Global Legal, Compliance, and IP functions. - Mr. Savage brings extensive legal leadership experience from the global pharmaceutical industry, previously serving at Teva Pharmaceuticals.

Governance Neutral

2026-10-19 19:02

- Lupin Limited announced the grant of 40,157 stock options to eligible employees under the Lupin Employees Stock Option Scheme 2025 on October 19, 2026. - Each option entitles the holder to one equity share at an exercise price of ₹2.00. - Options vest over a 3-year period starting one year from the grant date in equal annual instalments.

Business Update Neutral

2026-10-19 16:28

Concall Schedule Concall Date: November 04, 2026 Concall Time: 18:00 hours (IST)

Business Update Neutral

2026-10-15 18:09

- Lupin Limited informed the exchanges about an independent ESG rating assigned by NSE Sustainability Ratings and Analytics Limited. - The company received an ESG rating of '70' for FY26 compared to '71' for FY25. - The marginal decline of one point was driven by lower scores in the Social and Governance parameters.

Business Update Positive

2026-10-08 21:04

- Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe. - The product is indicated for the treatment and prophylaxis of hypoprothrombinemia and vitamin K-deficiency. - Phytonadione Injectable Emulsion had estimated annual sales of USD 52.3 million in the U.S. (IQVIA MAT Aug 2026).

Business Update Positive

2026-10-06 09:39

Lupin Limited launched Formoflo-G MDI, the world's first fixed-dose triple combination metered-dose inhaler for COPD management in India. - The product combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for moderate to severe COPD. - The launch targets over 55 million COPD patients in India, strengthening Lupin's position in the respiratory segment.

Business Update Positive

2026-10-01 10:08

- Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed the buyback of 30,559 shares. - MPPI has become a wholly owned subsidiary of Nanomi B.V. and a step-down wholly owned subsidiary of Lupin Limited effective October 01, 2026.

Routine Neutral

2026-09-28 15:43

- Trading window for designated persons and their immediate relatives will remain closed from October 01, 2026. - Closure will continue until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026. - Date of the Board Meeting will be intimated in due course.

Business Update Positive

2026-09-28 09:15

- Lupin Limited received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. - The product is an alternative administration option for adult patients requiring anticoagulation therapy who have difficulty swallowing tablets. - The product will be manufactured at Lupin's Somerset, New Jersey facility upon final approval.

Ownership Neutral

2026-09-21 16:26

- Allotment of 24,111 fully paid-up equity shares of ₹ 2/- each to employees under the Stock Option Plan (ESOP) on September 21, 2026. - The issued and paid-up share capital has increased to ₹ 91,45,79,944, comprising 45,72,89,972 equity shares.

Business Update Neutral

2026-09-08 16:36

- Investor Meet Schedule - Kotak Healthcare Conference: September 17, 2026 - J.P. Morgan India Conference: September 21, 2026

Business Update Positive

2026-09-04 17:40

- Lupin received U.S. FDA approval for Modafinil Tablets USP (100 mg & 200 mg) on Sept 4, 2026. - Indicated for excessive sleepiness related to narcolepsy, OSA, or SWD. - The reference listed drug had estimated annual sales of USD 70.7 million in the U.S.

Business Update Positive

2026-08-28 09:45

- Crisil ESG Ratings assigned Lupin an independent ESG Rating of 'Crisil ESG 69' and a Core ESG Rating of 'Crisil Core ESG 65' for FY26, placing the company in the 'Strong' category.

Ownership Neutral

2026-08-25 17:32

- Lupin allotted 30,967 fully paid-up equity shares of ₹2/- each on August 25, 2026, upon exercise of vested options under its ESOP plans. - The issued and paid-up share capital of the Company has increased to ₹91,45,31,722.

Business Update Neutral

2026-08-24 18:46

- Lupin Limited has received an independent ESG Rating of '60' from ESG Risk Assessments & Insights Limited, categorizing the company as 'Adequate'. - The company did not engage the rating agency for this assessment, which was based on publicly available data.

Business Update Positive

2026-08-20 10:48

- Lupin's subsidiary, VISUfarma B.V., signed an Exclusive License Agreement with Visus Therapeutics, Inc. for the commercialization of YUVEZZI™. - This proprietary ophthalmic product treats Presbyopia in adults within the European Union, UK, Switzerland, Norway, and Iceland. - Total potential consideration is up to €75 million, comprising a €20 million strategic investment and up to €55 million in regulatory and commercial milestone payments, plus tiered royalties on net sales. - The agreement is long-term, lasting until the 20th anniversary of the first commercial sale, with renewal options. - The partnership strengthens Lupin's ophthalmology portfolio and expands its specialty business in key European markets.

Governance Negative

2026-08-18 22:07

CRITICAL RED FLAG DETECTED

- Lupin Limited informed about the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company. - The demise occurred on August 17, 2026.

Business Update Positive

2026-08-17 12:20

- Lupin Limited announced it received final approval from the U.S. FDA for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg. The tablets are bioequivalent to Wakix®.

Business Update Positive

2026-08-12 17:48

- Reiterated full-year FY27 guidance for high single-digit revenue growth and EBITDA margins around 25%, with R&D spend expected to be around 8% of sales. - U.S. business is projected to be in the USD 1.1 billion to USD 1.2 billion range for FY27, with anticipated moderation in performance due to increased competitive intensity in key products like Mirabegron and Tolvaptan, before reverting to growth from FY28. - Plans to launch over 50 products in the U.S. in the next three years, including 10 exclusive first-to-files, five biosimilars, and two to three 505(b)(2) products. - India formulations business is expected to outperform the Indian Pharmaceutical Market (IPM) by 1.2x-1.3x, with a long-term target for novel proprietary products to contribute one-third of India revenues within 10 years. - Other Developed Markets and Emerging Markets are expected to sustain double-digit growth, with margin expansion anticipated in Europe due to strategic initiatives and an expanded portfolio. - Significant focus on building biosimilars (e.g., Pegfilgrastim, Ranibizumab) into a couple of hundred million dollars scale business across key markets in the next three years. - Noted positive compliance status with U.S. FDA EIRs for Ankleshwar and Somerset facilities (VAI status).

Business Update Positive

2026-08-10 18:01

- Lupin Limited announced U.S. FDA approval for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension (5 g/packet and 10 g/packet). - The approved drug is indicated for the treatment of hyperkalemia in adults. - The reference listed drug, Lokelma®, had estimated annual sales of USD 568 million in the U.S. (IQVIA MAT Jun 2026).

Routine Neutral

2026-08-10 16:15

New Filing detected. See link for details.

Routine Neutral

2026-08-07 21:39

New Filing detected. See link for details.

Financials Positive

2026-08-07 01:14

- Consolidated Revenue ₹82,172 mn vs ₹61,638 mn (▲33% YoY) - EBITDA ₹24,635 mn vs ₹16,414 mn (▲50% YoY) - PAT ₹14,150 mn vs ₹12,191 mn (▲16% YoY) - EBITDA Margin 30.0% vs 26.6% (▲340bps)

Financials Neutral

2026-08-06 22:14

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹82,172 mn vs ₹61,638 mn (▲33% YoY) - EBITDA ₹24,635 mn vs ₹16,414 mn (▲50% YoY) - PAT ₹14,150 mn vs ₹12,191 mn (▲16% YoY) - EBITDA Margin 30.0% vs 26.6% (▲340bps) - Launched new products including Azilsartan Medoxomil Tabs and Ranibizumab biosimilar in the US. - Received EMA approval for NaMuscla® extension and China approval for Oseltamivir Phosphate.

Financials Positive

2026-08-06 22:05

- Consolidated Revenue ₹82,172 Mn vs ₹61,638 Mn (▲33.3% YoY) - EBITDA ₹25,799 Mn vs ₹18,063 Mn (▲42.8% YoY) - PAT ₹14,170 Mn vs ₹12,215 Mn (▲16.0% YoY) - EBITDA Margin 31.4% vs 29.3% (▲210bps)

Financials Positive

2026-08-06 21:57

- Consolidated Revenue ₹82,768.9 million vs ₹62,683.4 million (▲31.9% YoY) - EBITDA ₹24,495.3 million vs ₹17,272.4 million (▲41.8% YoY) - PAT ₹14,169.8 million vs ₹12,214.6 million (▲16.0% YoY) - EBITDA Margin 29.6% vs 27.6% (▲200bps)

Governance Positive

2026-08-04 21:50

- Lupin Limited held its 44th Annual General Meeting (AGM) on August 04, 2026. - All five resolutions proposed in the AGM were duly passed by the members with requisite majority. - A final dividend of ₹18/- per Equity Share for the financial year ended March 31, 2026, was declared.

Business Update Positive

2026-07-31 17:10

- Lupin received U.S. FDA approval for its Abbreviated New Drug Application for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes in the United States. - The drug is indicated for the management of anxiety disorders. - The product had estimated annual sales of USD 77.9 million in the U.S. (IQVIA MAT May 2026).

Business Update Positive

2026-07-31 11:15

- Lupin announced U.S. FDA approval and launch of Sugammadex Injection in the United States on July 31, 2026. - The product is available in 200 mg/2 mL and 500 mg/5 mL single-dose vials. - It is bioequivalent to Bridion® Injection, indicated for the reversal of neuromuscular blockade.

Business Update Neutral

2026-07-22 18:45

- Concall Schedule - Concall Date: August 07, 2026 (Friday) - Concall Time: 16:30 Hrs IST

Business Update Positive

2026-07-21 07:24

- Lupin's subsidiary, Lupin Inc. U.S.A., granted an exclusive perpetual license for two oncology programs (LNP7457 & LNP8701) to Kaveri Therapeutics, Inc. U.S.A. - In exchange, Lupin Inc. received an 82.2% equity stake in Kaveri, with the license valued at USD 1.6 million. - Kaveri will advance these programs through global clinical trials and seek to raise additional capital.

Business Update Positive

2026-07-14 09:31

- Lupin recognized among India's Best Employers in the Nation-Builders Category by Great Place To Work® India 2026. - Ranks among the Top 14 organizations nationally.

Routine Neutral

2026-07-13 20:47

New Filing detected. See link for details.

Routine Neutral

2026-07-13 19:58

New Filing detected. See link for details.

Financials Positive

2026-07-08 16:40

- The Company will hold its 44th Annual General Meeting (AGM) on Tuesday, August 04, 2026. - The Board recommended a final dividend of ₹18/- per equity share (900%) for the financial year ended March 31, 2026. - The Record Date for determining entitlement for the dividend payment is Friday, July 17, 2026, subject to AGM approval.

Governance Positive

2026-07-08 16:36

- The 44th Annual General Meeting (AGM) is scheduled for Tuesday, August 04, 2026, at 04:00 p.m. IST via Video Conferencing/Other Audio Visual Means. - The Board had recommended a final Dividend of ₹18/- per equity share (900%) for the financial year ended March 31, 2026, subject to approval at the AGM. - The Record Date for determining the entitlement of members to receive this final dividend is Friday, July 17, 2026.

Ownership Neutral

2026-07-08 16:14

- Allotment of 2358 fully paid-up equity shares of ₹ 2/- each to employees under ESOP on July 08, 2026. - The issued and paid-up share capital of the Company has increased to ₹ 91,44,69,788, comprising 45,72,34,894 equity shares.

Business Update Positive

2026-07-06 10:15

- Lupin Limited has been named among the World's Most Sustainable Companies by TIME and Statista, making its debut on the 2026 list. - The company ranked 318th out of 750 global companies, recognized for its progress in environmental stewardship, responsible business practices, strong governance, and positive social impact.

Business Update Positive

2026-07-01 21:56

- Lupin received an Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset, New Jersey manufacturing facility. - The facility was issued a satisfactory Voluntary Action Indicated (VAI) classification. - The inspection was conducted from April 13-17, 2026.

Business Update Positive

2026-07-01 18:19

- Lupin's subsidiary, Nanomi, completed the acquisition of 11,794,497 shares in Multicare Pharmaceuticals Philippines, Inc. (MPPI) on July 01, 2026. - MPPI also completed a buy-back of 61,118 shares. - Post these transactions, Nanomi's shareholding in MPPI increased from 56.28% to 99.89%.

Business Update Positive

2026-07-01 16:46

- Lupin announced that the European Medicines Agency (EMA) has approved a change to the terms of marketing authorization for NaMuscla®. - The approval includes two new dosage strengths (62 mg and 83 mg capsules) and expands the indication to cover symptomatic treatment of myotonia in children (6-11 years) and adolescents (12-17 years) with non-dystrophic myotonic disorders. - NaMuscla is the only approved treatment for myotonia symptoms in Non-Dystrophic Myotonias (NDM) in Europe.

Business Update Positive

2026-06-30 21:14

- Lupin's Nomination and Remuneration Committee approved the grant of 65,251 stock options under the Lupin Employees Stock Option Scheme 2025. - The exercise price is ₹2.00/- per option, vesting over three years subject to performance conditions.

Routine Neutral

2026-06-26 16:37

- Trading window for designated persons and immediate relatives to close from July 01, 2026. - Closure is for the quarter ending June 30, 2026, ahead of unaudited financial results declaration. - The window will reopen 48 hours after the results are declared.

Business Update Positive

2026-06-26 09:39

- Lupin received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Enzalutamide Tablets (40 mg, 80 mg, 120 mg, and 160 mg). - These are bioequivalent to reference listed drug Xtandi® Tablets of Astellas.

Governance Positive

2026-06-22 19:58

- The Nomination and Remuneration Committee (NRC) granted 15,67,591 stock options under the Lupin Employees Stock Option Scheme 2025. - The effective date of grant is July 01, 2026, with an exercise price of ₹2.00 per option. - Options will vest over a period of three years, subject to performance conditions.

Business Update Positive

2026-06-17 17:06

- Lupin launched Azilsartan Medoxomil Tablets (40mg & 80mg) in the United States after U.S. FDA approval. - The product treats hypertension and is bioequivalent to Edarbi®. - Lupin is the exclusive first-to-file, eligible for 180-day generic drug exclusivity. - The estimated annual sales for the RLD were USD 53.5 million (IQVIA MAT April 2026).

Business Update Positive

2026-06-08 12:15

- Lupin Limited announced a strategic collaboration with LABORATORIOS ERN S.A. for the launch of Luforbec® (beclometasone/formoterol) pMDI in Spain. - Luforbec® is a fixed-dose combination inhaler for adult asthma and chronic obstructive pulmonary disease treatment.

Business Update Positive

2026-06-04 23:00

- Lupin received U.S. FDA approval for Ranluspec™ (ranibizumab) Injection. It is an interchangeable biosimilar referencing Lucentis® (Genentech). This approval expands Lupin's biosimilars portfolio and increases patient access to affordable vision therapies in the U.S.

Ownership Neutral

2026-06-03 17:38

- Allotment of 16,673 fully paid-up equity shares of ₹ 2/- each under ESOP on June 03, 2026. - Post-allotment, the issued and paid-up share capital increased to ₹ 91,44,65,072, comprising 45,72,32,536 equity shares.

Business Update Positive

2026-06-03 11:02

- Lupin Limited and Natco Pharma Limited received U.S. FDA approval for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. - The drug is indicated for metastatic breast cancer and unresectable or metastatic liposarcoma. - The reference listed drug (RLD Halaven®) had estimated annual sales of USD 43.7 million in the U.S. (IQVIA MAT April 2026).

Business Update Positive

2026-05-29 19:07

Lupin Limited announced on May 29, 2026, it received U.S. FDA approval for its Abbreviated New Drug Application for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets. Lupin is the exclusive first-to-file and is eligible for 180-day generic drug exclusivity for this product, which had estimated annual U.S. sales of USD 132.8 million (IQVIA MAT March 2026). The product will be manufactured at Lupin's Nagpur facility.

Business Update Neutral

2026-05-29 16:01

Lupin Limited provided an update on the acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. The transaction, through its wholly-owned subsidiary Nanomi B.V., was previously expected to be completed by the end of May 2026. It is now anticipated to be completed in July 2026, subject to certain closing conditions.

Business Update Positive

2026-05-28 11:11

Lupin Limited announced it shared positive Phase 1a data for LNP8701, a novel SOS1 inhibitor for metastatic solid tumors, at the ASCO Annual Meeting 2026. The study indicated LNP8701 was well tolerated with desirable safety and pharmacokinetics, showing favorable anti-tumor activity. Patients demonstrated stable disease, with some completing extended treatment cycles. Lupin plans to continue with its Phase 1b trial.

Business Update Positive

2026-05-28 09:49

Lupin Limited announced that its Ankleshwar facility in Gujarat, India, has received an Establishment Inspection Report (EIR) from the U.S. FDA. This follows the closure of a product-specific Pre-Approval Inspection conducted from March 2 to March 7, 2026, affirming the facility's compliance with regulatory standards.

Business Update Neutral

2026-05-25 17:26

Lupin Limited announced its participation in three Analyst/Institutional Investors Meets from June 02-04, 2026. These include the BofA Securities 2026 India Conference on June 02, the Morgan Stanley India Investment Forum 2026 on June 03, and the Citi India Conference 2026 on June 04. All meetings will be in-person group meetings, and presentations will align with existing company disclosures.

Business Update Positive

2026-05-22 15:51

Lupin Limited announced on May 22, 2026, that it received China's National Medical Products Administration (NMPA) approval for Oseltamivir Phosphate Oral Suspension. This approval, secured in partnership with Yabao Pharmaceuticals, marks Lupin's first product entry into the Chinese market, a significant milestone for its global expansion, particularly for pediatric influenza treatment and prevention.

Business Update Positive

2026-05-19 11:44

Lupin Limited has debuted in the Dow Jones Best-in-Class (DJBIC) World and Emerging Markets Indices for 2026, recognizing its strong commitment to sustainable, responsible, and ethical business practices. The company achieved an industry-leading score of 91/100 in the S&P Global Corporate Sustainability Assessment (CSA) 2025, reinforcing its credibility with global investors and strengthening its competitive positioning.

Business Update Positive

2026-05-18 21:09

Lupin Limited announced on May 18, 2026, that it has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials. This solution is indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The Reference Listed Drug (RLD) had estimated annual sales of USD 260.7 million in the U.S. as per IQVIA MAT March 2026.

Business Update Positive

2026-05-15 11:13

Lupin Limited has inaugurated 'Atharv Ability', an advanced multidisciplinary neuro-rehabilitation center in Naraina Vihar, Delhi. This world-class facility will provide comprehensive, specialized, and multidisciplinary care for adults and children with neurological disabilities, aiming to enhance mobility, improve quality of life, and support long-term recovery. This expansion follows successful launches in Mumbai (2023) and Hyderabad (2024), extending access to high-quality neuro-rehabilitation services in North India.

Business Update Neutral

2026-05-14 17:12

CRITICAL RED FLAG DETECTED

Management guided for FY27 revenue growth in high-single digits with an EBITDA margin of around 25%, down from the FY26 actual of 29.7%. This reduction is attributed to anticipated competition for key products like Tolvaptan and Mirabegron, and increased R&D expenditure. The effective tax rate is expected to be 25-26%, with R&D around 8% of sales. Key growth drivers include the US business, where the company expects to sustain 'billion dollar plus' revenues, driven by new product launches including biosimilars (Ravicti, Saxenda, Pegfilgrastim, Ranibizumab) and complex injectables. The India business is projected to outperform IPM, supported by a pipeline of over 80 new product launches. The recently acquired VISUfarma business is expected to contribute Euro 50-60 million in sales, aiming for USD 100 million in 2-3 years. The company received positive compliance updates from USFDA for its Goa facility and is on track with remediation efforts at Pithampur unit 2.

Business Update Positive

2026-05-13 18:28

Lupin Limited announced on May 13, 2026, it received U.S. FDA approval for its Abbreviated New Drug Applications for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials. The product, indicated for various gastric conditions, will be manufactured at Lupin's Nagpur facility in India. Famotidine Injection had estimated annual sales of USD 8.7 million in the U.S. (IQVIA MAT March 2026).

Business Update Neutral

2026-05-08 21:23

Lupin Limited informed about the availability of the audio recording for its Q4 FY26 Earnings Call, which was conducted on Friday, May 08, 2026, at 16:00 hrs (IST). The recording is accessible on the company's website via the provided link.

Financials Positive

2026-05-07 21:31

Lupin Limited reported strong Q4 FY2026 consolidated results with Operating Revenue at ₹7,391.9 Cr vs ₹5,562.2 Cr (▲32.9% YoY), EBITDA at ₹2,626.3 Cr vs ₹1,378.1 Cr (▲90.6% YoY), and PAT at ₹1,468.7 Cr vs ₹782.4 Cr (▲87.7% YoY). EBITDA Margin expanded significantly to 35.5% from 24.8% (▲1070bps). The Board also recommended a 900% dividend.

Governance Neutral

2026-05-07 21:23

Lupin Limited's Board of Directors, at its meeting on May 07, 2026, recommended the appointment of Deloitte Haskins & Sells Chartered Accountants LLP as the Statutory Auditors for a term of five consecutive years. This appointment will commence from the conclusion of the Forty-Fourth Annual General Meeting until the Forty-Ninth AGM, replacing BSR & Co. LLP, which completed its second term.

Financials Positive

2026-05-07 21:13

Standalone Revenue ₹5,234.6Cr vs ₹4,485.7Cr (▲16.7% YoY), EBITDA ₹2,281.6Cr vs ₹1,746.1Cr (▲30.7% YoY), PAT ₹2,163.7Cr vs ₹1,291.4Cr (▲67.6% YoY). EBITDA Margin 43.6% vs 38.9% (▲466bps). The company also recommended a dividend of ₹18/- per Equity Share.

Financials Positive

2026-05-07 21:02

Consolidated Revenue ₹7,474.66Cr vs ₹5,667.13Cr (▲31.9% YoY), EBITDA ₹2,354.24Cr vs ₹1,321.17Cr (▲78.2% YoY), PAT ₹1,468.67Cr vs ₹782.38Cr (▲87.7% YoY). EBITDA Margin 31.5% vs 23.3% (▲820bps). The Board also recommended a dividend of ₹18/- per equity share.

Business Update Positive

2026-05-05 09:13

Lupin Limited announced on May 5, 2026, that it has received U.S. FDA approval for its Abbreviated New Drug Applications for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. This product is indicated for the chronic management of patients with urea cycle disorders. The reference listed drug (RLD), Ravicti® Oral Liquid, had product sales of USD 337 million for the year ended December 2025.

Ownership Neutral

2026-05-04 12:24

Lupin Limited announced that its Operations and Finance Committee, on May 4, 2026, allotted 36,752 fully paid-up equity shares of ₹ 2/- each to employees upon the exercise of vested options under the Company's Stock Option plans. Consequently, the issued and paid-up share capital increased to ₹ 91,44,31,726, comprising 45,72,15,863 equity shares of ₹ 2/- each.

Financials Neutral

2026-04-23 18:29

Lupin Limited announced an Earnings Call for Q4 FY26 results on Friday, May 08, 2026, at 16:00 hrs IST. The company invited stakeholders to register for the Zoom call to discuss the financial performance.

Business Update Positive

2026-04-22 09:14

Lupin Limited announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. The launch follows FDA approval for the drug, which is bioequivalent to Xigduo® XR.

Business Update Negative

2026-04-18 11:58

CRITICAL RED FLAG DETECTED

Lupin Limited disclosed that the U.S. FDA completed an inspection of its Somerset, New Jersey manufacturing facility from April 13-17, 2026, issuing a Form-483 with three observations. The company committed to addressing these observations.

Business Update Positive

2026-04-17 17:15

Lupin Limited has incorporated a wholly owned subsidiary, 'Lupin (Thailand) Limited', on April 17, 2026. This new entity, with a registered capital of 3,000,000 Baht, will be engaged in importing, marketing, promoting, distributing, and selling pharmaceutical products in Thailand.

Business Update Negative

2026-04-17 06:53

CRITICAL RED FLAG DETECTED

Lupin's US subsidiary, LPI, settled antitrust litigation with Humana Inc. for USD 30 million, denying anticompetitive behavior. The settlement amount was already provisioned in prior consolidated financial results, resolving the lawsuits and avoiding further litigation costs.

Routine Neutral

2026-04-10 19:52

New Filing detected. See link for details.

Business Update Positive

2026-04-09 09:03

Lupin Limited granted 6,495 stock options to its employees on April 09, 2026, under the ESOP 2011 plan. The exercise price is ₹2.00 per option, with a vesting schedule of 25% annually over four years after one year from the grant date.

Business Update Positive

2026-04-08 17:22

Lupin Limited announced on April 8, 2026, that it received U.S. FDA approval for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in various strengths, along with tentative approval for another strength, for the United States market.

Business Update Positive

2026-04-07 21:23

Lupin Limited announced on April 7, 2026, that it received U.S. FDA approval for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg, for the United States market.

Business Update Positive

2026-04-07 10:56

Lupin Limited announced it received the Great Place To Work® Certification™ for 2026-27, recognized for its commitment to employee experience and inclusive culture with 85% employee participation. This global recognition underscores positive workplace practices.

Routine Neutral

2026-04-06 18:05

Lupin Limited filed a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate from MUFG Intime India Private Limited confirms the dematerialization and transfer activities for the quarter.

Business Update Positive

2026-04-02 10:59

Lupin Limited completed the acquisition of VISUfarma B.V., a European specialty ophthalmology company. This expands Lupin's ophthalmology portfolio to over 60 products and strengthens its presence across Europe. VISUfarma reported €53m revenue in 2025.

Business Update Positive

2026-04-01 18:44

Lupin's subsidiary Nanomi B.V. will acquire a 43.38% minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) for up to USD 39.6 million by May 2026. This move aims to make MPPI a wholly-owned subsidiary, strengthening Lupin's market standing in the Philippines and unlocking long-term value.

Business Update Positive

2026-04-01 17:26

Lupin's subsidiary Nanomi B.V. has completed the acquisition of VISUfarma B.V., Netherlands, making VISUfarma and its subsidiaries wholly owned subsidiaries of Nanomi, effective April 01, 2026, as per earlier intimations.

Business Update Positive

2026-03-31 08:29

Lupin Limited announced on March 31, 2026, that it has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL Single-Dose Vial), a bioequivalent to Merck's Bridion® Injection.

Ownership Positive

2026-03-30 09:41

Lupin's wholly-owned subsidiary, Nanomi B.V., increased its indirect shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI) from 51% to 56.28% after MPPI bought back shares from its existing shareholders. This strengthens Lupin's control over MPPI.

Routine Neutral

2026-03-25 15:54

LUPIN Limited announced the closure of its trading window from April 01, 2026, until 48 hours after the declaration of audited financial results for the quarter and financial year ending March 31, 2026. The Board Meeting date will be intimated later.

Business Update Positive

2026-03-25 09:17

Lupin Limited announced on March 25, 2026, that it received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Pitolisant Tablets (4.45mg and 17.8mg). The product, bioequivalent to Wakix®, will be manufactured at Lupin's Nagpur facility.

Ownership Neutral

2026-03-24 12:43

On March 24, 2026, Lupin's Operations and Finance Committee allotted 135,892 equity shares under its ESOP plans. This increased the company's issued and paid-up share capital to ₹ 91,43,58,222, comprising 45,71,79,111 equity shares of ₹ 2/- each.

Business Update Positive

2026-03-19 08:17

Lupin Manufacturing Solutions (LMS) announced a strategic expansion of its Dabhasa, India manufacturing facility. This expansion will scale its peptide building-blocks platform and CRDMO capabilities, enhancing advanced development and flexible manufacturing to meet global demand for advanced pharmaceutical solutions.

Business Update Positive

2026-03-17 12:06

Lupin Limited has entered into a Licensing and Supply Agreement with Zydus Lifesciences Limited to co-market Zydus' innovative Semaglutide Injection in India. This partnership aims to expand patient access to advanced therapies for diabetes and weight management. Lupin will pay upfront licensing fees and milestone payments to Zydus.

LUPIN

Lupin Ltd

Price Chart

Filing History

Unlock Full History